Phase IV Commitments For Registries Likely To Increase, Genentech Says
Executive Summary
Manufacturers should expect more postmarketing commitments for safety and pregnancy exposure registries for chronic disease medications, Genentech Senior Epidemiologist Haley Kaplowitz, PhD, said during the Drug Information Association conference on pharmacovigilance in Washington, D.C. Jan. 14
You may also be interested in...
Pregnancy Registries Should Not Be Mandated In Drug Label, Amgen Tells FDA
Industry is challenging one of the central components of FDA's proposed rule on pregnancy and lactation labeling - that any existing registries for patients should be included in labeling
Pregnancy Registries Should Not Be Mandated In Drug Label, Amgen Tells FDA
Industry is challenging one of the central components of FDA's proposed rule on pregnancy and lactation labeling - that any existing registries for patients should be included in labeling
Genentech Raptiva To Undergo 5,000-Patient Postmarketing Safety Study
Genentech will conduct a 5,000-patient study of the incidence of adverse events associated with Raptiva (efalizumab) as a condition of FDA approval of the psoriasis treatment